OVERVIEW

Use of biologics in the management of axial spondyloarthropathies (axSpA) has become well established in psoriatic arthritis and ankylosing spondylitis. The spectrum of axSpA is becoming better understood and now includes inflammation in the absence of observable damage using radiographic techniques (nr-axSpA). In nr-axSpA the impact on quality of life is rated as high as in more advanced conditions such as AS and use of biologic agents is increasingly being seen as an appropriate approach. A number of manufacturers are studying the clinical benefit of NCEs and existing approved agents in this condition, resulting an a highly dynamic future market.

The RealTime Dynamix: Axial Spondyloarthritis report series provides a detailed and timely look at current and future trends in the AS and nr-axSpA market, and the effects of the future shifting landscape. The bi-annual releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures. The report also includes variable content addressing current key issues that is updated every six months. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the ax-SpA market make this an essential tool for companies competing in the space, as well as those with near term plans to enter it.

SAMPLE & METHODOLOGY

Each Quarter, ~100 US rheumatologists provide their responses to an online survey. Respondents may only participate in one survey per year. Respondents are recruited from the Spherix Network, a proprietary group of clinical physicians meeting our strict screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output. Additionally, this gives us the opportunity to easily revisit physicians in order to uncover even more insight on strategically important findings.

KEY QUESTIONS ANSWERED

- What are the clinical practice patterns for managing and treating AS and nr-axSpA and how do they differ, if at all?
- How do US rheumatologists diagnose and differentiate AS and nr-axSpA?
- Which pharmaceutical companies offer the best support in ankylosing spondylitis (AS) and nr-axSpA?
- How do payer policies impact the use of the biologics in the treatment of AS and nr-axSpA?
- What is the relative performance of approved agents in the management of AS?
- What is the level of unmet need in AS compared to other conditions and what attributes are most desired in new agents?
- How aware of pipeline agents are US rheumatologists, which ones are they excited about, and how do they project future use?
- How much of an advance is Cosentyx over other treatment options for treating AS?

Products Profiled

Commercial Products, AS:
- UCB (Cimzia), Pfizer (Enbrel, Xeljanz), AbbVie (Humira), Janssen (Remicade, Simponi, Stelara), Incyte/Lilly (Olumiant), Hospira (Inflectra), Novartis (Cosentyx)

Pipeline Agents, AS/nr-axSpA:
- Janssen (Stelara, ustekinumab, IL-12/23-inhibitor), Sun/Merck (Tildrakizumab, IL-23-inhibitor), GSK (Guselkumab, IL-23-inhibitor), BI/AbbVie (Risankizumab, IL-23-inhibitor), Pfizer (Xeljanz-tofacitinib, JAK-inhibitor), Lilly/Incyte (Olumiant-baricitinib, JAK-inhibitor), Eli-Lilly (Taltz-ixekizumab, IL-17-inhibitor)

Key Dates

Q2 2017
- Field: June 5, 2017
- Publish: June 30, 2017

Q4 2017
- Field: November 22, 2017
- Publish: December 15, 2017

Deliverables
- PowerPoint report
- On-site presentation and interpretation
- Proprietary Questions
- Custom cross-tabulations

Related Reports 2017

- RealTime Dynamix: Psoriatic Arthritis US
- RealTime Dynamix: Psoriatic Arthritis EU
- RealTime Dynamix: RA US
- RealTime Dynamix: RA EU
- RealTime Dynamix: Rheumatology NP/PA
- RealWorld Dynamix: Biologic/JAK Switching in Psoriatic Arthritis US
- RealWorld Dynamix: Biologic/Otezla Switching in Psoriatic Arthritis EU
- RealWorld Dynamix: Biologic/JAK Switching in Rheumatoid Arthritis US
- RealWorld Dynamix: Biologic/JAK Switching in Rheumatoid Arthritis EU

To order or to get more information, please contact info@spherixglobalinsights.com or call 800-661-0571 (US) or (41) 41 747 18 72 (EU)